Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Sunday.
A number of other brokerages have also recently commented on NAGE. Roth Capital reiterated a "buy" rating and set a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th. Canaccord Genuity Group upped their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, June 10th.
View Our Latest Stock Analysis on NAGE
Niagen Bioscience Price Performance
Shares of NAGE opened at $13.44 on Friday. Niagen Bioscience has a 1-year low of $2.31 and a 1-year high of $14.49. The stock has a market cap of $1.06 billion, a price-to-earnings ratio of 79.06 and a beta of 2.08. The firm has a 50 day simple moving average of $10.06 and a 200-day simple moving average of $7.38.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
